Literature DB >> 25047817

NPPB is a novel candidate biomarker expressed by cancer-associated fibroblasts in epithelial ovarian cancer.

Kate Lawrenson1, Barbara Grun, Nathan Lee, Paulette Mhawech-Fauceglia, Jenny Kan, Steve Swenson, Yvonne G Lin, Tanja Pejovic, Joshua Millstein, Simon A Gayther.   

Abstract

Most solid tumors contain cancer-associated fibroblasts (CAFs) that support tumorigenesis and malignant progression. However, the cellular origins of CAFs in epithelial ovarian cancers (EOCs) remain poorly understood, and their utility as a source of clinical biomarkers for cancer diagnosis has not been explored in great depth. Here, we report establishing in vitro and in vivo models of CAFs in ovarian cancer development. Normal ovarian fibroblasts and mesenchymal stem cells cultured in the presence of EOC cells acquired a CAF-like phenotype, and promoted EOC cell migration in vitro. CAFs also promoted ovarian cancer growth in vivo in both subcutaneous and intraperitoneal murine xenograft assays. Molecular profiling of CAFs identified gene expression signatures that were highly enriched for extracellular and secreted proteins. We identified novel candidate CAF-specific biomarkers for ovarian cancer including NPPB, which was expressed in the stroma of 60% primary ovarian cancer tissues (n = 145) but not in the stroma of normal ovaries (n = 4). NPPB is a secreted protein that was also elevated in the blood of 50% of women with ovarian cancer (n = 8). Taken together, these data suggest that the tumor stroma is a novel source of biomarkers, including NPPB, that may be of clinical utility for detection of EOC.
© 2014 UICC.

Entities:  

Keywords:  BNP; NPPB; cancer-associated fibroblast; fibroblast; microarray; microenvironment; ovarian cancer; stroma; xenograft

Mesh:

Substances:

Year:  2014        PMID: 25047817      PMCID: PMC4289413          DOI: 10.1002/ijc.29092

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  28 in total

1.  Human ovarian carcinoma–associated mesenchymal stem cells regulate cancer stem cells and tumorigenesis via altered BMP production.

Authors:  Karen McLean; Yusong Gong; Yunjung Choi; Ning Deng; Kun Yang; Shoumei Bai; Lourdes Cabrera; Evan Keller; Laurie McCauley; Kathleen R Cho; Ronald J Buckanovich
Journal:  J Clin Invest       Date:  2011-08       Impact factor: 14.808

2.  Senescent fibroblasts promote neoplastic transformation of partially transformed ovarian epithelial cells in a three-dimensional model of early stage ovarian cancer.

Authors:  Kate Lawrenson; Barbara Grun; Elizabeth Benjamin; Ian J Jacobs; Dimitra Dafou; Simon A Gayther
Journal:  Neoplasia       Date:  2010-04       Impact factor: 5.715

3.  Development of a multimarker assay for early detection of ovarian cancer.

Authors:  Zoya Yurkovetsky; Steven Skates; Aleksey Lomakin; Brian Nolen; Trenton Pulsipher; Francesmary Modugno; Jeffrey Marks; Andrew Godwin; Elieser Gorelik; Ian Jacobs; Usha Menon; Karen Lu; Donna Badgwell; Robert C Bast; Anna E Lokshin
Journal:  J Clin Oncol       Date:  2010-04-05       Impact factor: 44.544

4.  Neuropeptide Y, B-type natriuretic peptide, substance P and peptide YY are novel substrates of fibroblast activation protein-α.

Authors:  Fiona M Keane; Naveed A Nadvi; Tsun-Wen Yao; Mark D Gorrell
Journal:  FEBS J       Date:  2011-03-09       Impact factor: 5.542

5.  Bone marrow stromal cells protect myeloma cells from bortezomib induced apoptosis by suppressing microRNA-15a expression.

Authors:  Mu Hao; Li Zhang; Gang An; Hengxing Meng; Youjin Han; Zhenqing Xie; Yan Xu; Changhong Li; Zhen Yu; Hong Chang; Lugui Qiu
Journal:  Leuk Lymphoma       Date:  2011-05-03

6.  Fibroblasts in omentum activated by tumor cells promote ovarian cancer growth, adhesion and invasiveness.

Authors:  Jing Cai; Huijuan Tang; Linjuan Xu; Xiaoyi Wang; Chun Yang; Shasha Ruan; Jianfeng Guo; Sha Hu; Zehua Wang
Journal:  Carcinogenesis       Date:  2011-10-21       Impact factor: 4.944

7.  Integrated genomic analyses of ovarian carcinoma.

Authors: 
Journal:  Nature       Date:  2011-06-29       Impact factor: 49.962

8.  ABCG2 is a direct transcriptional target of hedgehog signaling and involved in stroma-induced drug tolerance in diffuse large B-cell lymphoma.

Authors:  R R Singh; K Kunkalla; C Qu; E Schlette; S S Neelapu; F Samaniego; F Vega
Journal:  Oncogene       Date:  2011-05-30       Impact factor: 9.867

9.  BRCAness profile of sporadic ovarian cancer predicts disease recurrence.

Authors:  Weiya Z Wysham; Paulette Mhawech-Fauceglia; Hong Li; Laura Hays; Suzanna Syriac; Tijana Skrepnik; Jay Wright; Nupur Pande; Maureen Hoatlin; Tanja Pejovic
Journal:  PLoS One       Date:  2012-01-11       Impact factor: 3.240

10.  Origins of the tumor microenvironment: quantitative assessment of adipose-derived and bone marrow-derived stroma.

Authors:  Shannon Kidd; Erika Spaeth; Keri Watson; Jared Burks; Hongbo Lu; Ann Klopp; Michael Andreeff; Frank C Marini
Journal:  PLoS One       Date:  2012-02-20       Impact factor: 3.240

View more
  13 in total

1.  A COL11A1-correlated pan-cancer gene signature of activated fibroblasts for the prioritization of therapeutic targets.

Authors:  Dongyu Jia; Zhenqiu Liu; Nan Deng; Tuan Zea Tan; Ruby Yun-Ju Huang; Barbie Taylor-Harding; Dong-Joo Cheon; Kate Lawrenson; Wolf R Wiedemeyer; Ann E Walts; Beth Y Karlan; Sandra Orsulic
Journal:  Cancer Lett       Date:  2016-09-05       Impact factor: 8.679

Review 2.  Molecular mechanism underlying the tumor-promoting functions of carcinoma-associated fibroblasts.

Authors:  Yali Han; Yanwen Zhang; Tanghong Jia; Yuping Sun
Journal:  Tumour Biol       Date:  2015-02-15

Review 3.  Biological heterogeneity and versatility of cancer-associated fibroblasts in the tumor microenvironment.

Authors:  Luke Bu; Hideo Baba; Naoya Yoshida; Keisuke Miyake; Tadahito Yasuda; Tomoyuki Uchihara; Patrick Tan; Takatsugu Ishimoto
Journal:  Oncogene       Date:  2019-02-28       Impact factor: 9.867

4.  Discover the molecular biomarker associated with cell death and extracellular matrix module in ovarian cancer.

Authors:  Qiang Liu; Jianxin Guo; Jinghong Cui; Jing Wang; Ping Yi
Journal:  Biomed Res Int       Date:  2015-03-16       Impact factor: 3.411

5.  Tumor T1 Relaxation Time for Assessing Response to Bevacizumab Anti-Angiogenic Therapy in a Mouse Ovarian Cancer Model.

Authors:  Murali K Ravoori; Masato Nishimura; Sheela P Singh; Chunhua Lu; Lin Han; Brian P Hobbs; Sunila Pradeep; Hyun J Choi; James A Bankson; Anil K Sood; Vikas Kundra
Journal:  PLoS One       Date:  2015-06-22       Impact factor: 3.240

Review 6.  Targeting Stromal-Cancer Cell Crosstalk Networks in Ovarian Cancer Treatment.

Authors:  Tsz-Lun Yeung; Cecilia S Leung; Fuhai Li; Stephen S T Wong; Samuel C Mok
Journal:  Biomolecules       Date:  2016-01-06

7.  Characterization of Gene Expression Patterns among Artificially Developed Cancer Stem Cells Using Spherical Self-Organizing Map.

Authors:  Akimasa Seno; Tomonari Kasai; Masashi Ikeda; Arun Vaidyanath; Junko Masuda; Akifumi Mizutani; Hiroshi Murakami; Tetsuya Ishikawa; Masaharu Seno
Journal:  Cancer Inform       Date:  2016-08-16

8.  Functional prediction of long non-coding RNAs in ovarian cancer-associated fibroblasts indicate a potential role in metastasis.

Authors:  Fatemeh Vafaee; Emily K Colvin; Samuel C Mok; Viive M Howell; Goli Samimi
Journal:  Sci Rep       Date:  2017-09-04       Impact factor: 4.379

Review 9.  The metabolic cross-talk between epithelial cancer cells and stromal fibroblasts in ovarian cancer progression: Autophagy plays a role.

Authors:  Chanitra Thuwajit; Alessandra Ferraresi; Rossella Titone; Peti Thuwajit; Ciro Isidoro
Journal:  Med Res Rev       Date:  2017-09-19       Impact factor: 12.944

10.  miR-148a-3p suppresses epithelial ovarian cancer progression primarily by targeting c-Met.

Authors:  Wen Wang; Jing Dong; Maoxiu Wang; Shujuan Yao; Xiangyu Tian; Xiujuan Cui; Shijie Fu; Shiqian Zhang
Journal:  Oncol Lett       Date:  2018-02-23       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.